Sponsor
Rosa L. Delauro
Representative · D-CT
Representative · D-CT
The bill reduces early commercial promotion of newly approved drugs to protect patients from premature, potentially misleading advertising and pressure to adopt new products, but it risks delaying awareness and access to beneficial treatments, imposes economic losses on marketing‑related businesses, and concentrates discretion over exceptions in the HHS Secretary.
Patients (especially those with chronic conditions and Medicare/Medicaid beneficiaries) will face fewer early commercial promotions for newly approved drugs during the first 3 years, reducing exposure to potentially misleading advertising and decreasing pressure on clinicians and insurers to adopt drugs before stronger post‑approval safety and effectiveness evidence accumulates.
Patients and the public will see less misleading or incomplete promotional content about new drugs on social media during the initial evidence‑gathering period, improving the overall quality of information circulating online.
Patients (especially those with chronic conditions and Medicare/Medicaid beneficiaries) may be less aware of newly approved treatments for up to three years, delaying access or uptake of drugs that could benefit them.
Drug sponsors, advertising firms, and small media businesses will lose an early marketing window, likely reducing short‑term revenue for those firms and raising costs for patient outreach through alternative channels.
Patients may have reduced ability to receive direct-to-consumer information that supports patient-driven questions and conversations about new treatment options, constraining some aspects of patient autonomy.
Based on analysis of 2 sections of legislative text.
Bars DTC advertising for newly approved prescription drugs for three years after approval, allows a narrow third-year waiver, and permits later bans if postmarket safety shows significant harm.
Official title: To amend the Federal Food, Drug, and Cosmetic Act to restrict direct-to-consumer drug advertising.
Introduced February 7, 2025 by Rosa L. Delauro · Last progress February 7, 2025
Prohibits direct-to-consumer (DTC) advertising of newly approved prescription drugs for the first three years after FDA approval, with a limited waiver option in the third year if the Secretary of Health and Human Services finds an affirmative public health value. After the initial three-year window, the Secretary may ban DTC advertising for a drug if new post-approval evidence reveals significant adverse health effects; FDA must revise drug-advertising rules within one year. The rule applies to drugs approved on or after the date one year before enactment.